Table 2

Results after ¹⁰³Pd plaque for subfoveal neovascularisation

Eye number	Vision (20/x)	Follow up (months)																		Initial vision	Last ETDRS vision	Lines of vision	Last reported vision	Ophthalmic status
Eye number	Vision (20/x)	3	6	9	12	15	18	21	24	30	36	42	48	54	60	66	72	78	84	Initial vision	Last ETDRS vision	Lines of vision	Last reported vision	Ophthalmic status
CF = counting fingers, LP = light perception, HM = hand movements, RR = radiation retinopathy; AMD = age related macular degeneration, PDT = photodynamic therapy, TTT = transpupillary thermotherapy.
1	400	400	400	400	400	400	320	320	250	250	250	400	400	NA	NA	NA	CF		400	CF	>−6	CF		Regressed to dry AMD
2	63	40	32	32	32	32	NA	32	32	32	NA	32	40	40	32	32				63	32	3	32	Stabilised PED
3	40	63	63	40	63	50	40	40	40	63	NA	50	50	NA	200	NA	100	100	100	40	200	>−6	100	Eccentric recurrence at 82 months
4	250	200	200	400	320	320	320	100	100	400	200	80	80	63	63					250	63	6	63	Regressed to dry AMD
5	63	63	63	50	50	63	NA	80	63	40	40	50	NA	NA	40					63	40	2	40	Regressed to dry AMD+
6	400	200	125	100	100	100	160	NA	100	125	200	250	250	640	NA	NA	CF	CF	CF	400	CF	>−6	CF	Improved but not dry
7	32	20	16	20	NA	25	25	32	32	32	32	32	63	400	NA	CF			32	400	>−6	CF		Regressed to dry AMD
8	40	25	160	250	250	NA	200	NA	200	400	400	400	CF	NA	CF	CF	CF	CF	40	CF	>−6	CF		Regressed to disciform scar
9	40	40	NA	63	80	500	NA	NA	NA	CF	NA	400	400							40	400	>−6	400	Regressed to disciform scar
10	80	100	NA	NA	NA	NA	NA	400	160	CF	160	320	400	200	200	200	320			80	320	−6	320	Regressed to dry AMD
11	100	100	NA	NA	100	NA	NA	NA	NA	NA	NA	HM	HM						100	HM	>−6	HM	Vitreous	haemorrhage at 24 months
12	160	80	63	80*	250*	200*	200*	250*	250*	250*	500*	400*	400*	400*	NA	LP*			160	500	>−6	LP		SRN, re-irradiated at 9 months*
13	200	100	100	100	NA	63	NA	100	500	200	HM	CF	NA	CF	CF	CF			125	HM	>−6	CF	Vitreous haemorrhage at 36 months
14	32	25	20	25	25	20	20	20	20	20	25									32	25	1	25	Regressed to dry AMD
15	50	100	63	100	125	160	200	200	200	250	320	400	CF							50	320	>−6	CF	TTT given at 36 months
16	32	25	20	20	20	40	20	25	25	40	50	200								32	40	−1	200	PDT given at 30 months
17	50	32	32	20	25	50	25	NA	25	32										50	32	2	32	No progression
18	63	80	125	NA	NA	NA	250	250	250	500										63	500	>−6	500	Regressed to disciform scar
19	40	40	40	32	40	NA	50	50	160	320	CF									40	160	−6	CF	PDT given at 24 months
20	125	100	125	125	200	320	400	200	200	CF										125	200	−2	CF	PDT given at 24 months
21	100	100	100	100	125	125	NA	100	125											100	125	−1	125	No progression, deceased
22	50	63	50	63	100	100	125	250	320	320	NA	CF								50	250	>−6	CF	Regressed to disciform scar, deceased
23	32	63	63	100	100	160	200	125												32	125	−6	125	Progressed
24	100	100	100	125	125	125	NA	125												100	125	−1	125	Regressed to dry AMD
25	160	250	200	200	NA	NA	200	200												160	200	−1	200	Improved but not dry, deceased
26	32	63	80	160																32	160	>−6	160	Progressed
27	50	100	160	400	NA	NA	NA	NA	HM	NA	HM	HM	HM	CF						50	400	>−6	CF	Regressed to disciform scar
28	63	50	32																	63	32	3	32	Regressed to dry AMD
29	200	200	320																	200	320	−2	320	Progressed, deceased
30	63	100																		63	100	−2	100	Lost to follow up
31	125	25																		125	25	>+6	25	Lost to follow up
Mean follow up (months)																33.3